No damages are in play in Immunex v. Sandoz, but Amgen's market cap popped $10 billion Monday on news that it successfully defended two patents on its rheumatoid arthritis drug Enbrel.
August 14, 2019 at 02:01 PM
1 minute read
Welcome to Skilled in the Art. I’m Law.com IP reporter Scott Graham, and I’m back from a week’s hiatus and ready to catch up on some IP news. A quick rundown:
• Amgen’s defense of rheumatoid arthritis drug adds $10 billion to its market cap.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
